---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-101688"
form_type: "8-K"
ticker: "HRMY"
cik: "0001802665"
company_name: "Harmony Biosciences Holdings, Inc."
filed_at: "2025-10-23T23:59:59+00:00"
generated_at: "2026-05-17T02:32:59.871724+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Harmony Biosciences raises 2025 revenue guidance after Q3 WAKIX revenue of $239M (+29% YoY)

## Summary
- Preliminary Q3 2025 WAKIX net revenue of ~$239M, up 29% year-over-year.
- Average patient count rose by ~500 to 8,100 in Q3, the largest quarterly increase ever.
- 2025 revenue guidance raised to $845-$865M from prior $820-$860M.
- Full Q3 2025 earnings and conference call scheduled for November 4, 2025.

## SEC filing metadata
- accession: 0001104659-25-101688
- form_type: 8-K
- ticker: HRMY
- cik: 0001802665
- company_name: Harmony Biosciences Holdings, Inc.
- filed_at: 2025-10-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802665/000110465925101688/0001104659-25-101688-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802665/000110465925101688/hrmy-20251023x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-101688
- JSON: https://secwatch.observer/filing/0001104659-25-101688.json
- Plain text: https://secwatch.observer/filing/0001104659-25-101688.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.